Grupo Español de Tratamiento de Tumores Digestivos
LightNews LightNews
banner
ttdgroup.bsky.social
Grupo Español de Tratamiento de Tumores Digestivos
@ttdgroup.bsky.social
4 followers 12 following 120 posts
TTD Group-Grupo Español de Tratamiento de los Tumores Digestivos. Fomentamos la investigación clínica, traslacional y epidemiológica de los cánceres digestivos. www.ttdgroup.org
Posts Replies Media Videos
Pinned
ttdgroup.bsky.social
Grupo Español de Tratamiento de Tumores Digestivos @ttdgroup.bsky.social · Jul 21
📢SAVE THE DATE ‼

👉33 @GrupoTTD International Symposium

📅10-11-12 Dec. 2025
Oviedo (Spain)

🗣️A meeting point for leading specialists who will present the latest data related to the progress in the investigation of the digestive tumours

#TTD25

www.ttdgroup.org/formacion/si...
ttdgroup.bsky.social
📍Estudio GENERATE (JCOG1611). Estudio comparativo en cáncer de páncreas metastásico en 1ªlínea de tratamiento
https://ascopubs.org/doi/10.1200/JCO.24.00936

👉Estudio comparativo MFOLFIRINOX, S-IROX y nab-paclitaxel-gemcitabina

(🧵1/2)
Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial
PURPOSEModified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) and nab-paclitaxel + gemcitabine are recommended as first-line treatments for metastatic pancreatic cancer. S-1, irinotecan, and oxaliplatin (S-IROX) demonstrated activity ...
ascopubs.org
November 11, 2025 at 8:02 AM
ttdgroup.bsky.social
📍Perioperative camrelizumab➕rivoceranib vs surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
🔗https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01720-9/abstract
🧵(1/3)
#TTDUpdates
⤵️
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
Perioperative camrelizumab plus rivoceranib significantly improved EFS compared with surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence.
www.thelancet.com
November 10, 2025 at 3:04 PM
ttdgroup.bsky.social
📍Cáncer de hígado: el reto pendiente en el tumor 'silencioso'

Compartimos el artículo de opinión del Dr. Fernando Rivera (presidente del TTD y jefe del servicio de oncología médica de HU Marqués de Valdecilla) en ABC con motivo del #Díamundialcancerhígado

www.abc.es/salud/enferm...
October 30, 2025 at 2:40 PM
ttdgroup.bsky.social
📍#DíaMundialCáncerHígado

El TTD recuerda que prevención, detección precoz e investigación cooperativa son esenciales para salvar vidas🔬

👉Los ensayos multicéntricos coordinados permiten avanzar hacia tratamientos➕personalizados

✍️https://efesalud.com/cancer-higado-ensayos-investigacion-dia-mundial
October 30, 2025 at 8:40 AM
ttdgroup.bsky.social
📍No te pierdas el #TTDCOLOQUIO Novedades en terapias dirigidas en CCRm
📅25NOV
⏰17h
Coordina: Dra Rith Vera
📢Dres. F. Salvà (VHebron)
J. Alcaide(HUR Málaga)
J. Sastre(HUC San Carlos)
https://www.ttdgroup.org/contenidos/formacion/workshop/evento.aspx
Patrocina Merck👉Abierto a especialistas interesados
October 27, 2025 at 6:30 PM
ttdgroup.bsky.social
📍Pembrolizumab + Chemotherapy as Perioperative Therapy in Resectable Gastric & GEJ Cancer
https://ascopubs.org/doi/10.1200/JCO-25-00486 
Phase III, randomized trial (n = 1,007)
✅ Design:Neoadjuvant + adjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy ✅ Median follow-up:59.9 months
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study
We report results of the final analysis of overall survival (OS) and patient-reported outcomes from the phase III KEYNOTE-585 (ClinicalTrials.gov identifier: NCT03221426) study. Participants with previously untreated, locally advanced, resectable gastric ...
ascopubs.org
October 27, 2025 at 8:03 AM
ttdgroup.bsky.social
TTD JOURNAL CLUB-Investigación de vanguardia en tumores digestivos
👉#ESMO25
📢Escucha a la Dra. Ana Mª López con las últimas novedades en:
📽️BILIOPANCREÁTICOS https://lnkd.in/d574m8Jn
📽️HEPATOCARCINOMA https://lnkd.in/deTNgH_y
📽️HEPAT. estado intermedio https://lnkd.in/dj8Bb8d5
October 24, 2025 at 8:03 AM
ttdgroup.bsky.social
TTD JOURNAL CLUB-Investigación de vanguardia en tumores digestivos
👉TTD-#ESMO25. CÁNCER ESOFAGOGÁSTRICO
📢Escucha a la Dra. Mireia Gil destacando las últimas novedades.
📽️Adenocarcinoma gástrico vimeo.com/showcase/119...
📽️Carcinoma Escamoso Esófago vimeo.com/showcase/119...
October 23, 2025 at 11:03 AM
ttdgroup.bsky.social
📍Neoadjuvant CTLA-4/PD-(L)1 Blockade in Resectable dMMR/MSI-High Gastroesophageal Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/41021880
Pooled individual patient-level analysis (n=197 patients)
✅ICIs→higher pCR(61.9%vs3.7%)&MPR(78.6%vs10%) vsFLOT
✅Lower ypN+(14%vs37%)&ypT(OR 16.4;p<001)
⬇️
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis - PubMed
In resectable dMMR/MSI-H GEA, neoadjuvant ICIs significantly increase pathologic response and downstaging versus FLOT, with comparable EFS/OS with surgery with or without chemotherapy. The higher proportion of ypN0 and lack of ypT4 after neoadjuvant ICIs versus FLOT should drive preoperative treatme …
pubmed.ncbi.nlm.nih.gov
October 23, 2025 at 7:03 AM
ttdgroup.bsky.social
📍Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer
https://pubmed.ncbi.nlm.nih.gov/40779895
Meta-analysis of phase3⃣trials(MATTERHORN&KEYNOTE-585)
✅FLOT+IO>Cis/5FU+IO for EFS (HR 0.79; p=0.021)
👉IO+FLOT emerges as standard-of-care candidate in resectable GE adenocarcinoma
October 22, 2025 at 10:04 AM
ttdgroup.bsky.social
📍CHALLENGE
https://pubmed.ncbi.nlm.nih.gov/40450658/
👉Ensayo fase 3
👉Ejercicio estructurado 3 años post-QT adyuvante en cáncer colon resecado
↑ supervivencia libre enfermedad (HR 0,72; p=0,02) y ↑ SG a 8 años (90,3% vs 83,2%)
👉Evidencia nivel 1 del beneficio oncológico del ejercicio
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer - PubMed
A 3-year structured exercise program initiated soon after adjuvant chemotherapy for colon cancer resulted in significantly longer disease-free survival and findings consistent with longer overall survival. (Funded by the Canadian Cancer Society and others; CHALLENGE ClinicalTrials.gov number, NCT008 …
pubmed.ncbi.nlm.nih.gov
October 17, 2025 at 3:03 PM
ttdgroup.bsky.social
📍The CANOPTIPHYS randomised controlled trial
https://pubmed.ncbi.nlm.nih.gov/40450796
Ensayo en ≥65 años con CCR:ejercicio preoperatorio (2-3 sem) vs cuidados estándar
👉No⬇️complicaciones postoperatorias(48,1% vs62,5%)
👉Mostró tendencia➕en recuperación y viabilidad del programa domiciliario
Effect of preoperative exercise on postoperative complications after colorectal cancer surgery in older people with low physical fitness: The CANOPTIPHYS randomised controlled trial - PubMed
In this study of older patients with low physical fitness awaiting colorectal cancer surgery, we could not demonstrate an influence of preoperative exercise on postoperative complications, discharge destination or length of hospital stay. These results should be interpreted with caution due to a sma …
pubmed.ncbi.nlm.nih.gov
October 16, 2025 at 3:03 PM
ttdgroup.bsky.social
📍Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
https://pubmed.ncbi.nlm.nih.gov/36610262 
➡️Estudio retrospectivo que analiza la prevalencia de expresión de CLDN18.2“. 
(🧵1/2)
Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer - PubMed
CLDN18.2 expression in advanced GC/GEJC was associated with some clinical and molecular features but had no impact on treatment outcomes with chemotherapy or checkpoint inhibition. CLDN18.2-positive also had no impact on overall survival. This information could be useful to interpret the results fro …
pubmed.ncbi.nlm.nih.gov
October 15, 2025 at 3:03 PM
ttdgroup.bsky.social
📍Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinoma
https://pubmed.ncbi.nlm.nih.gov/40513139/ 
➡️FGFR2b identifica un subgrupo molecular independiente en cáncer gástrico avanzado con una potencial terapia dirigida
(🧵1/2)
Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinoma - PubMed
This study revealed limited overlap of FGFR2b overexpression with currently actionable biomarkers, suggesting FGFR2b is a novel biomarker that identifies a distinct GC/GEJC patient population who may benefit most from an FGFR2b-targeting therapy.
pubmed.ncbi.nlm.nih.gov
October 14, 2025 at 3:04 PM
ttdgroup.bsky.social
📍Enrique Aranda, jefe de Oncología Médica de H.U. Reina Sofia:"Los programas de cribado de cáncer salvan muchas vidas"

El expresidente del TTD, referente en tumores digestivos, acaba de ser reconocido con un premio a su trayectoria clínica y científica👏👏

www.diariocordoba.com/cordoba-ciud...
El cordobés Enrique Aranda, jefe de Oncología Médica del hospital Reina Sofía: 'Los programas de cribado de cáncer salvan muchas vidas'
Este doctor, referente nacional en tumores digestivos, acaba de ser reconocido con un premio a su trayectoria clínica y científica
www.diariocordoba.com
October 14, 2025 at 7:27 AM
ttdgroup.bsky.social
📍XI Carrera de las Ciudades contra el cáncer de páncreas🏃‍♀️
Un año más, el Grupo TTD se suma como patrocinador en Madrid.

📆
16 NOV/VALENCIA
16 NOV/BURGOS
23 NOV/ALICANTE
23 NOV/MADRID
23 NOV/ORENSE
30 NOV/AVILA
CARRERA VIRTUAL DEL 10 AL 23 DE NOV🏃‍♀️

ℹ️https://carreracancerpancreas.es
October 13, 2025 at 8:28 AM
ttdgroup.bsky.social
📍JNCI 2025: Early-onset CRC(<50y) rising in 🇦🇺🇨🇦🇬🇧🇺🇸
✅Risk 5–7x higher in 1990vs1960 cohorts
✅Annual↑~8.5%(20–39y), up to10–11%in women

#CRC 
(1/2)🧵
October 3, 2025 at 7:02 AM
ttdgroup.bsky.social
📍Targeting YAP in imatinib-resistant GIST
✅Persister cells showed↑nuclear YAP after imatinib
✅YAP inhibition (verteporfin, XAV-939)↓YAP&↑ apoptosis
✅Combo imatinib+verteporfin delayed regrowth (xenografts)
(1/2)🧵
October 1, 2025 at 7:02 AM
ttdgroup.bsky.social
🔹PASS-01(phase II,1LmPDAC):mFOLFIRINOX vsGnP
https://ascopubs.org/doi/10.1200/JCO-25-00436 
✅OS:13.2vs12.7m(NS)
✅ORR:41%vs30%
⚠️More neutropenia with mFOLFIRINOX
📌Subtypes: basal-like→GnP; classical→OS favored GnP; early CA19-9 drop>20%→↑PFS
📢Biomarkers&transcriptomic subtypes matter in PDAC
September 29, 2025 at 7:02 AM
ttdgroup.bsky.social
📌 KEYNOTE-585 Final Analysis
🔗 https://ascopubs.org/doi/10.1200/JCO-25-00486

🧑‍⚕️ Resectable GC/GEJ (~1000 pts)
💊 Pembro+CT vs placebo+CT
📊 OS 71.8 vs 55.7 mo (HR 0.86) | EFS HR 0.81
🧬 ↑pCR | ⚖️ Similar G≥3 AEs | 🙂 QoL preserved
❓MATTERHORN (+) vs KEYNOTE-585 (−): backbone, design or biology?
September 25, 2025 at 7:03 AM
ttdgroup.bsky.social
📢Contribuimos a la investigación con ensayos clínicos, estudios traslacionales y registros, claves para desarrollar mejores terapias frente al cáncer🧪
Con la premisa de mejorar la calidad asistencial: el foco puesto en el paciente🔦

#WorldCancerResearchDay #WCRD #SomosTTD
September 24, 2025 at 6:02 AM
ttdgroup.bsky.social
📍MATTERHORN
https://www.nejm.org/doi/full/10.1056/NEJMoa2503701
Durvalumab+FLOT mejora SLE en ADC gástrico/UGE en escenario perioperatorio.
🔹SLE a 2 años: 67,4% vs. 58,5% (HR 0,71)
🔹RC patológica: 19.2% vs 7.2%
⏳Resultados de SG pendientes

#TTDUpdates
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer | NEJM
Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but recurrence rates remain hig...
www.nejm.org
September 22, 2025 at 7:02 AM
ttdgroup.bsky.social
📍#TTDCOLOQUIO 'Dianas terapéuticas en cáncer gástrico/UGE: necesidades hoy y mañana-HER negativo'
📅23-S
⏰17h

Coordina: Dr.Rivera, presidente TTD (H. Univ.Valdecilla)

📢Dras.Fleitas; Calvo; Martínez
Patrocina: Astellas, BeOne

www.ttdgroup.org/contenidos/f...

✅Abierto a especialistas
September 19, 2025 at 8:52 AM
ttdgroup.bsky.social
📍DESTINY-Gastric04
https://www.nejm.org/doi/abs/10.1056/NEJMoa2503119
T-DXd mejora SG vs paclitaxel+ramucirumab en 2L en gástrico HER2+metastásico
🔹SG:14.7 vs 11.4 meses (HR 0.7)
🔹SLP:6,7 vs 5,6 meses(HR 0.74)
🔹TRO:44,3% vs 29,1%
🔍HER2+confirmado por biopsia tras progresión a trastuzumab
#TTDUpdates
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer | NEJM
On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal junctio...
www.nejm.org
September 18, 2025 at 7:02 AM
ttdgroup.bsky.social
📍IWWD/VIKINGO (Watch&Wait en cáncer de recto)
Mayor riesgo de metástasis a distancia tras recrecimiento local en cáncer de recto
🔗https://ascopubs.org/doi/10.1200/JCO.24.00405
Datos combinados de los registros IWWD y VIKINGO: 👁️Estrategia Watch&Wait tras respuesta clínica completa
🧵(1/2)👇
Risks of Organ Preservation in Rectal Cancer: Data From Two International Registries on Rectal Cancer
PURPOSEOrgan preservation has become an attractive alternative to surgery (total mesorectal excision [TME]) among patients with rectal cancer after neoadjuvant therapy who achieve a clinical complete response (cCR). Nearly 30% of these patients will ...Increased risk of distant metastases with local...
ascopubs.org
September 15, 2025 at 7:02 AM